Alexandra Bosoanca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Bosoanca has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Sima
Second Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania
2 shared publications - Ana Maria Mihai
Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
2 shared publications - Andrada Tarau
Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
2 shared publications - Florina Cristiana Lucaciu
Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
2 shared publications - Madalina-Ianca Suba
Doctoral School, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
2 shared publications - Monica Marc
Pulmonology University Clinic, Clinical Hospital of Infectious Diseases and Pneumophthisiology “Dr. Victor Babeș”, 13 Gheorghe Adam Street, RO-300310 Timisoara, Romania
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 654
Antibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis
Background: Adults hospitalized with COVID-19, influenza A/B, or respiratory syncytial virus (RSV) frequently receive empirical antibiotics, but antibiotic prescribing, confirmed bacterial co-infection, antimicrobial resistance (AMR), and outcomes have not been jointly synthesized across these infections. Methods: We conducted a PRISMA 2020 systematic review and meta-analysis of 39 studies including 839,531 hospitalized adults. Random-effects models with Freeman–Tukey double-arcsine transformation pooled prevalence estimates; sensitivity and publication-bias analyses were performed where appropriate. Results: Pooled antibiotic use was 62.56% (95% CI, 53.75–70.97%) for COVID-19, 57.48% (25.76–86.09%) for influenza A/B, and 76.03% (67.62–83.53%) for RSV, with very high heterogeneity. Confirmed bacterial co-infection was lower: 5.31% (3.43–7.56%), 18.66% (9.98–29.30%), and 24.36% (18.53–30.70%), respectively. Prescribing-to-confirmed infection ratios ranged from 3.0 to 46.2. AMR evidence was restricted to COVID-19 studies and was dominated by carbapenem-resistant Gram-negative organisms, mainly in secondary, ICU-associated, or healthcare-associated infections. Confirmed bacterial complications were associated with ICU admission, longer hospitalization, and higher mortality. Conclusions: Antibiotic prescribing exceeded confirmed bacterial infection across all viral groups, but estimates require cautious interpretation due to heterogeneity, diagnostic uncertainty, observational evidence, and the absence of low-risk-of-bias studies. The evidence base was dominated by COVID-19 cohorts, while influenza A/B and RSV data, especially virus-specific AMR evidence, remain limited. COVID-19-specific AMR findings should not be generalized to influenza A/B or RSV. Virus-specific stewardship should prioritize rapid diagnostics, systematic sampling, reassessment, and de-escalation when bacterial infection is not confirmed.
- 30 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 654
Open AccessAntibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis
Background: Adults hospitalized with COVID-19, influenza A/B, or respiratory syncytial virus (RSV) frequently receive empirical antibiotics, but antibiotic prescribing, confirmed bacterial co-infection, antimicrobial resistance (AMR), and outcomes have not been jointly synthesized across these infections. Methods: We conducted a PRISMA 2020 systematic review and meta-analysis of 39 studies including 839,531 hospitalized adults. Random-effects models with Freeman–Tukey double-arcsine transformation pooled prevalence estimates; sensitivity and publication-bias analyses were performed where appropriate. Results: Pooled antibiotic use was 62.56% (95% CI, 53.75–70.97%) for COVID-19, 57.48% (25.76–86.09%) for influenza A/B, and 76.03% (67.62–83.53%) for RSV, with very high heterogeneity. Confirmed bacterial co-infection was lower: 5.31% (3.43–7.56%), 18.66% (9.98–29.30%), and 24.36% (18.53–30.70%), respectively. Prescribing-to-confirmed infection ratios ranged from 3.0 to 46.2. AMR evidence was restricted to COVID-19 studies and was dominated by carbapenem-resistant Gram-negative organisms, mainly in secondary, ICU-associated, or healthcare-associated infections. Confirmed bacterial complications were associated with ICU admission, longer hospitalization, and higher mortality. Conclusions: Antibiotic prescribing exceeded confirmed bacterial infection across all viral groups, but estimates require cautious interpretation due to heterogeneity, diagnostic uncertainty, observational evidence, and the absence of low-risk-of-bias studies. The evidence base was dominated by COVID-19 cohorts, while influenza A/B and RSV data, especially virus-specific AMR evidence, remain limited. COVID-19-specific AMR findings should not be generalized to influenza A/B or RSV. Virus-specific stewardship should prioritize rapid diagnostics, systematic sampling, reassessment, and de-escalation when bacterial infection is not confirmed.
- Open Access
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2890
Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up
Context/Objectives: In patients with COPD (chronic obstructive pulmonary disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection represents an overlap of viral injury on a lung already affected by pathological mucus, altered mucociliary clearance, chronic inflammation, and impaired antiviral immunity. Methods: A focused narrative review (2020–2025) was conducted using clinical, experimental, and consensus evidence. The evidence was synthesized qualitatively, with priority given to cohort studies, meta-analyses, and mechanism-focused studies with clinical relevance. Results: Mucus obstruction (“mucus plugs”) is frequent in COPD (41–67%) and is associated with unfavorable outcomes. COPD also increases the risk of post-COVID respiratory sequelae. Bacterial coinfection at presentation is uncommon (3–5%), whereas secondary bacterial infections are more frequent (14–18%), especially in severe disease requiring intensive care, where VA-LRTI/VAP (ventilator-associated lower respiratory tract infection/ventilator-associated pneumonia) become predominant. Sepsis, whether viral or mixed, reflects disease severity and may contribute to functional decline and susceptibility to reinfections; however, the concept of a post-acute “sepsis legacy” in COPD after COVID-19 should currently be regarded as a clinically plausible but still emerging hypothesis rather than an established COPD-specific outcome. During recovery, acute exacerbation risk rises to 5.6% versus 3.9%, peaking in the first 30 days after severe disease (aHR ≈ 8.14). Persistent dyspnea and reduced DLCO (diffusing capacity for carbon monoxide) suggest ARDS-related injury, tissue remodeling, and microvascular dysfunction. Conclusions: In COPD, post-COVID respiratory sequelae result from the interaction of mucus, immunity, and infectious/sepsis-related complications. The first post-discharge month is a critical period requiring careful risk stratification and targeted follow-up.
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2890
Open AccessPost-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up
Context/Objectives: In patients with COPD (chronic obstructive pulmonary disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection represents an overlap of viral injury on a lung already affected by pathological mucus, altered mucociliary clearance, chronic inflammation, and impaired antiviral immunity. Methods: A focused narrative review (2020–2025) was conducted using clinical, experimental, and consensus evidence. The evidence was synthesized qualitatively, with priority given to cohort studies, meta-analyses, and mechanism-focused studies with clinical relevance. Results: Mucus obstruction (“mucus plugs”) is frequent in COPD (41–67%) and is associated with unfavorable outcomes. COPD also increases the risk of post-COVID respiratory sequelae. Bacterial coinfection at presentation is uncommon (3–5%), whereas secondary bacterial infections are more frequent (14–18%), especially in severe disease requiring intensive care, where VA-LRTI/VAP (ventilator-associated lower respiratory tract infection/ventilator-associated pneumonia) become predominant. Sepsis, whether viral or mixed, reflects disease severity and may contribute to functional decline and susceptibility to reinfections; however, the concept of a post-acute “sepsis legacy” in COPD after COVID-19 should currently be regarded as a clinically plausible but still emerging hypothesis rather than an established COPD-specific outcome. During recovery, acute exacerbation risk rises to 5.6% versus 3.9%, peaking in the first 30 days after severe disease (aHR ≈ 8.14). Persistent dyspnea and reduced DLCO (diffusing capacity for carbon monoxide) suggest ARDS-related injury, tissue remodeling, and microvascular dysfunction. Conclusions: In COPD, post-COVID respiratory sequelae result from the interaction of mucus, immunity, and infectious/sepsis-related complications. The first post-discharge month is a critical period requiring careful risk stratification and targeted follow-up.
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Pneumologia
- Vol. 74 (1) , 120-124
Unexpected evolution and delayed diagnosis in a case of persistent bronchopneumonia in an elderly patient
Introduction: Lung adenocarcinoma represents the most frequent histopathological variant of bronchopulmonary neoplasm, but the invasive mucinous subtype is rarely encountered, difficult to diagnose, has a poor prognosis, with rapid progression and poor treatment response. Case Description: A 78-year-old female patient, non-smoker, without exposure to respiratory irritants, presented with dry cough, dyspnea on minimal exertion, and loss of appetite. Thoracic computed tomography (CT) and blood analysis suggested an infectious etiology. Thoracentesis and bronchoscopy were performed, and the results of the bronchial aspirate and bronchoalveolar lavage initially supported the hypothesis of bronchopneumonia. Following antibiotic treatment, the patient’s condition initially improved, but she returned to the emergency department with aggravated symptoms and imaging progression. A CT-guided lung punch biopsy was performed, and the histopathological examination revealed the presence of an invasive mucinous adenocarcinoma. The evolution was unfavorable, followed by death. Discussion: The initial imaging appearance, weakly suggestive of a proliferative pathology, posed difficulties in early diagnosis and initiation of specific treatment. The biological samples contributed to delaying the oncological diagnosis by supporting the hypothesis of an infectious pathology. Conclusions: This case highlights the importance of heightened clinical suspicion and thorough evaluation in situations with atypical evolution and insufficient response to antibiotic treatment.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Pneumologia
- Vol. 74 (1) , 120-124
Open AccessUnexpected evolution and delayed diagnosis in a case of persistent bronchopneumonia in an elderly patient
Introduction: Lung adenocarcinoma represents the most frequent histopathological variant of bronchopulmonary neoplasm, but the invasive mucinous subtype is rarely encountered, difficult to diagnose, has a poor prognosis, with rapid progression and poor treatment response. Case Description: A 78-year-old female patient, non-smoker, without exposure to respiratory irritants, presented with dry cough, dyspnea on minimal exertion, and loss of appetite. Thoracic computed tomography (CT) and blood analysis suggested an infectious etiology. Thoracentesis and bronchoscopy were performed, and the results of the bronchial aspirate and bronchoalveolar lavage initially supported the hypothesis of bronchopneumonia. Following antibiotic treatment, the patient’s condition initially improved, but she returned to the emergency department with aggravated symptoms and imaging progression. A CT-guided lung punch biopsy was performed, and the histopathological examination revealed the presence of an invasive mucinous adenocarcinoma. The evolution was unfavorable, followed by death. Discussion: The initial imaging appearance, weakly suggestive of a proliferative pathology, posed difficulties in early diagnosis and initiation of specific treatment. The biological samples contributed to delaying the oncological diagnosis by supporting the hypothesis of an infectious pathology. Conclusions: This case highlights the importance of heightened clinical suspicion and thorough evaluation in situations with atypical evolution and insufficient response to antibiotic treatment.